QIAGEN (QGEN) Company Report

Qiagen reported strong organic growth of 7% in Q1 and 6% in Q2 and Q3, driven by its strategy and the resilience of its 85% consumables-based business.
The company announced a CEO transition and issued a cautious Q4 guidance, citing NIH funding constraints and academic shutdowns impacting instrumentation sales.
Key growth drivers include QuantiFERON (TB testing) and strong placements of QIAstat-Dx instruments, with an anticipated inflection in the sample technology business in 2026 due to new platform launches.
The recent acquisition of Pars Biosciences is expected to contribute $40 million in revenue next year and, despite creating approximately 200 basis points of margin headwinds in 2026, Qiagen aims for flattish margins and plans to update its 31% midterm margin target for 2028.

1 day ago

Transcript

QGEN Discusses Strong 2025 Performance, CEO Transition, and 2026 Growth Drivers

QGEN

CEO Change

Product Launch

Guidance Update

QGEN's organic growth was strong in the first three quarters of 2025, with 7% in Q1 and 6% in Q2 and Q3, outperforming life science tools peers, largely due to its resilient consumables-based business.
The company is undergoing a CEO transition, with Thierry transitioning out after six years as CEO, and a search for a successor is underway with a typical European timeframe of three to six months.
Qiagen anticipates significant product launches in 2026, including the fifth generation of QuantiFERON (with some products launching in 2026 and 2027) and new sample prep platforms like QIAsprint and QIAmini (both launching mid-2026), which are expected to be important inflection points for the Sample Tech segment.
For 2026, the consensus EPS is around $2.50, and despite anticipated headwinds of approximately 200 basis points from the Pars acquisition, currency, and tariffs, margins are expected to remain flattish due to operational improvements and a favorable product mix.

1 day ago

Transcript

QIAGEN Discusses Q3 Performance, CEO Transition, and 2026 Outlook

QGEN

Product Launch

M&A

CEO Change

QIAGEN reported 7% growth in Q1 and 6% growth in Q2 and Q3, with 85% of its business in resilient consumables.
The company is undergoing a CEO transition, with the search for a successor expected to conclude within 3 to 6 months.
Key product developments include the upcoming fifth generation of QuantiFERON (launching 2026-2027) and new sample prep platforms like QIAsymphony Connect (H1 2026) and QIAsprint (mid-2026), which targets a new high-throughput market.
The Pars acquisition is projected to contribute $40 million in revenue in 2026 and is expected to be margin accretive over time.
Despite an anticipated 200 basis points of margin headwind for 2026, QIAGEN expects margins to remain flattish due to operational efficiencies and a favorable product mix, with a midterm target of 31% by 2028.

1 day ago

Transcript

QIAGEN Announces CEO Transition, Share Buyback, and Strategic Growth Initiatives

QGEN

CEO Change

Share Buyback

M&A

QIAGEN is undergoing a CEO transition, with current CEO Thierry stepping down after 6 years, and the board expects to find a successor within 3 to 6 months. No strategic change is anticipated.
The company announced a $500 million share buyback to be executed early next year (2026) and started paying a dividend this year, indicating a strong focus on shareholder returns.
QIAGEN acquired Parse Biosciences, expected to generate $20 million in revenues in 2024 and $60 million in 2025, significantly boosting its sample prep business. The QuantiFERON business continues to perform strongly, with $2.5 billion in cumulative revenues since 2012 and a large untapped market.
QIAGEN expects to update and increase its midterm EBIT margin target of at least 31% by 2028, despite anticipated headwinds in 2026 from the Parse acquisition, currency, and tariffs, with overall margins expected to be at least at this year's level.

2 days ago

Transcript

QIAGEN Announces Share Buyback, Acquisition, and CEO Transition

QGEN

Share Buyback

M&A

CEO Change

QIAGEN announced a $500 million share buyback to be executed early next year, following $300 million buybacks in the current and previous years, and also started paying a dividend this year.
The company acquired Parse Biosciences, which is expected to generate $20 million in revenues for 2024 and $60 million in 2025, significantly contributing to sample prep growth.
QIAGEN is undergoing a CEO transition, with the current CEO stepping down after 10 years, and the board is seeking a successor, with no strategic changes expected.
Key growth drivers include QuantiFERON, which is outgrowing its $600 million long-term target and addressing a market where 60% still uses older tests, and QIAstat-Dx, which continues strong double-digit growth with over 150 placements per quarter and recent four FDA approvals.
Despite near-term headwinds from the Parse acquisition, currency, and tariffs, QIAGEN expects to maintain its EBIT margin at least at this year's level for next year, with a midterm target of at least 31% by 2028 which is expected to be increased.

2 days ago

Transcript

QIAGEN Announces CEO Transition, Strategic Acquisitions, and Capital Allocation Plans

QGEN

CEO Change

M&A

Share Buyback

QIAGEN is undergoing a CEO transition, with Thierry stepping down; a new CEO is expected to be identified within three to six months, with no anticipated change to the company's current strategy.
The company acquired Parse Biosciences, projected to generate $20 million in revenues in 2024 and $60 million in 2025, significantly enhancing its sample prep business. Key product lines like QuantiFERON are on track to exceed their $600 million long-term target, and QIAstat-Dx continues to deliver strong double-digit growth, bolstered by four recent FDA approvals that expand its U.S. market menu.
QIAGEN plans a $500 million share buyback for early next year, building on $300 million in previous years, and has initiated a dividend, reflecting robust cash generation.
Despite near-term headwinds from the Parse acquisition, currency, and tariffs, the company expects to maintain its margin level next year and anticipates increasing its midterm EBIT margin target of at least 31% by 2028.

2 days ago

Transcript

QIAGEN to Launch Three New Automation Platforms and Targets Sample Technology Growth

QGEN

Product Launch

New Projects/Investments

Guidance Update

QIAGEN is set to launch three new automation platforms – QIAsymphony Connect, QIAsprint Connect, and QIAmini – between 2025 and H2 2026, aiming to expand its automation portfolio and address various throughput needs.
The company projects its sample technology business to grow from $642 million in 2024 to at least $750 million by 2028, with growth driven by these new automation solutions and high-value applications.
QIAGEN is expanding into high-growth application areas, including liquid biopsy and oncology, which are growing over 35% year-over-year for the company, and single-cell analysis, a market expected to reach over $2.1 billion by 2029.
The company holds a significant market share of 55% to 60% in sample technology, with 30,000 instruments already placed, and anticipates substantial new placements from the upcoming product launches, such as 10,000 for QIAsprint Connect and over 100,000 for QIAmini.

Nov 21, 2025, 2:00 PM

Transcript

QIAGEN Outlines Growth Strategy for Sample Technologies Business

QGEN

Product Launch

New Projects/Investments

Guidance Update

QIAGEN's sample technologies business generated $642 million in revenue in 2024 and is projected to grow to at least $750 million by 2028.
The company is launching three new automation platforms (QIAsymphony Connect, QIAsprint Connect, and QIAmini) between 2026 and H2 2026, targeting significant market placements.
Strategic growth areas include high-value applications like liquid biopsy, which is growing at 35% year over year, and the expansion into single-cell genomics through the acquisition of Pars Biosciences, a market expected to reach over $2.1 billion by 2029.

Nov 21, 2025, 2:00 PM

Transcript

QIAGEN Unveils New Automation Platforms and Growth Strategy for Sample Technologies

QGEN

Product Launch

New Projects/Investments

Guidance Update

QIAGEN is launching three new automation platforms for sample technologies: QIAsymphony Connect, QIAsprint Connect, and QIAmini, with launches scheduled between late 2025 and H2 2026.
These new systems target diverse lab needs, including high-throughput oncology applications (QIAsymphony Connect), large-scale sample processing (QIAsprint Connect, with a potential for 10,000 placements), and budget-friendly automation for smaller labs (QIAmini, with a potential for over 100,000 placements).
The company's sample technologies business generated $642 million in revenue in 2024 and is projected to grow to at least $750 million by 2028.
QIAGEN is expanding into high-growth application areas such as liquid biopsy, which is experiencing over 35% year-over-year growth and represents a $6 billion market potential in oncology, and single-cell analysis, a market expected to reach over $2.1 billion by 2029.
Sample technologies are a foundational element of QIAGEN's strategy, enabling the company to establish a presence in labs and facilitate the cross-selling of its downstream solutions like digital PCR and next-generation sequencing.

Nov 21, 2025, 2:00 PM

Transcript

QIAGEN Provides Update on Sample Technologies Growth and Market Expansion

QGEN

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

QIAGEN's Sample Technologies segment, a leader in molecular workflows, generated $642 million in net sales for 2024 and targets ~$650 million for 2025 and ≥$750 million for 2028 at constant exchange rates.
The company is addressing a growing $2 billion+ market opportunity with its comprehensive portfolio of >350 different sample kits and state-of-the-art automation solutions.
QIAGEN is driving growth in high-value applications, including >35% growth within its liquid biopsy portfolio , and is expanding into the ~$2.1 billion single-cell market by 2029 through Parse Biosciences.
New automation systems, such as QIAsprint Connect (launch 2025) and high-throughput automation (launch 2026), are planned to further scale automation capabilities.

Nov 21, 2025, 2:00 PM

Presentation

Earnings Transcripts

Quarterly earnings call transcripts for QIAGEN.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are QIAGEN's strategic priorities?How is QIAGEN positioned vs competitors?How did QIAGEN do last quarter?

Let Fintool AI Agent track QIAGEN's earnings for you

Get instant analysis when filings drop